Although the current patient with ALK rearrangement-positive LCNEC received ALK-TKI, alectinib and achieved a PR for 11 months, the brain tumor had acquired resistance to ALK-TKI similar to a case previously reported [12]. The gene discussed is ALK; the disease is large cell neuroendocrine carcinoma.